Quick Answer
Nuvectis Pharma, Inc. reported Cash and Equivalents of $31.63 million for fiscal year 2025.
Nuvectis Pharma, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $31.63M | +70.7% |
| 2024 | $18.53M | -3.1% |
| 2023 | $19.13M | -4.3% |
| 2022 | $19.99M | +248.2% |
| 2021 | $5.74M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $35.44M | +106.4% | +32.3% |
| June 30, 2025 | $26.79M | +47.9% | -10.3% |
| March 31, 2025 | $29.86M | +53.4% | +61.1% |
| December 31, 2024 | $18.53M | -3.1% | +7.9% |
| September 30, 2024 | $17.17M | -22.2% | -5.2% |
| June 30, 2024 | $18.12M | -26.4% | -6.9% |
| March 31, 2024 | $19.46M | +25.8% | +1.8% |
| December 31, 2023 | $19.13M | -4.3% | -13.3% |
- Nuvectis Pharma, Inc. showed an increase of +70.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, Nuvectis Pharma, Inc.’s cash and equivalents has grown by 450.9% (from $5.74 million to $31.63 million).
- The most recent figure is from Nuvectis Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: